Moving on up.

Headline: Combo BRAF / MEK inhibition is moving up in the treatment algorithm for advanced melanoma. The Aussie single arm phase 2 NeoCombi trial enrolled 35 patients with resectable BRAF-mutant melanoma with clinical nodal or in-transit mets (stage III) who received neoadjuvant oral dabrafenib 150 mg twice daily + trametinib 2 mg daily x 12 weeks prior to resection. Impressively, at time of surgery all patients exhibited at least a partial path response and half actually achieved a complete pathologic response. TBL: Half of patients with resectable clinical stage III cutaneous BRAF-mutant melanoma can achieve a complete pathologic response just with 3 months of pills with breakfast and dinner. | Long, Lancet Oncol 2019